Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatorenal syndrome.

R Bataller1, P Ginès, V Arroyo

  • 1Liver Unit, Institut de Malalties Digestives, Hospital Clínic, Barcelona, Spain.

Clinics in Liver Disease
|March 10, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular evidence of mother-to-infant transmission of hepatitis G virus among women without known risk factors for parenteral infections.

Journal of clinical microbiology·1999
Same author

Hepatorenal syndrome and ascites--questions and answers.

Liver·1999
Same author

Comparative study of a modified competitive RT-PCR and Amplicor HCV monitor assays for quantitation of hepatitis C virus RNA in serum.

Journal of medical virology·1999
Same author

Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites.

Gastroenterology·1999
Same author

Vascular endothelial growth factor production in peritoneal macrophages of cirrhotic patients: regulation by cytokines and bacterial lipopolysaccharide.

Hepatology (Baltimore, Md.)·1999
Same author

Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.

The Journal of pharmacology and experimental therapeutics·1999
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

Hepatorenal syndrome (HRS) is kidney failure in advanced cirrhosis patients. Recent updates revised HRS diagnosis and types, highlighting circulatory dysfunction as a key cause needing further therapeutic research.

Area of Science:

  • Nephrology
  • Hepatology
  • Gastroenterology

Background:

  • Hepatorenal syndrome (HRS) is a severe complication in patients with advanced liver disease and ascites.
  • It represents a functional renal failure driven by circulatory dysfunction, specifically renal vasoconstriction due to splanchnic arterial vasodilation.
  • Recent revisions have updated the diagnostic criteria and classification of HRS.

Purpose of the Study:

  • To summarize the current understanding of hepatorenal syndrome, including revised diagnostic criteria and underlying pathophysiology.
  • To discuss the limitations of current treatments, particularly liver transplantation, due to patient survival rates.
  • To highlight emerging therapies and the need for further research in managing HRS.

Main Methods:

  • Review of recent literature and clinical guidelines on hepatorenal syndrome.

Related Experiment Videos

  • Analysis of the pathophysiology involving renal hypoperfusion and circulatory dysfunction.
  • Discussion of treatment options, including liver transplantation and novel therapeutic approaches.

    • Main Results:

    • Hepatorenal syndrome is characterized by significant kidney hypoperfusion resulting from renal vasoconstriction.
    • The underlying cause is arterial vasodilation within the splanchnic circulation, leading to a perceived underfilling of systemic arterial circulation.
    • Liver transplantation remains the optimal treatment, but limited applicability due to short patient survival is a major challenge.

    Conclusions:

    • Hepatorenal syndrome requires updated diagnostic criteria and understanding of its clinical types.
    • While liver transplantation is the best treatment, its accessibility is restricted.
    • Systemic vasoconstrictors and transjugular intrahepatic portosystemic shunt (TIPS) show promise, necessitating further prospective studies for HRS management.